<!DOCTYPE html>
<html lang="en-us">
<head>

  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="generator" content="Source Themes Academic 3.1.1">
  <meta name="generator" content="Hugo 0.51" />
  <meta name="author" content="Stef van Buuren">

  
  
  
  
    
  
  <meta name="description" content="Context and Objective: GH therapy increases growth and adult height in Turner syndrome (TS). The benefit to risk ratio of adding the weak androgen oxandrolone (Ox) to GH is unclear. Design and Participants: A randomized, placebo-controlled, double-blind, dose-response study was performed in 10 centers in The Netherlands. One hundred thirty-three patients with TS were included in age group 1 (2-7.99 yr), 2 (8-11.99 yr), or 3 (12-15.99 yr). Patients were treated with GH (1.33 mg/m(2). d) from baseline, combined with placebo (Pl) or Ox in low (0.03 mg/kg. d) or conventional (0.06 mg/kg. d) dose from the age of 8 yr and estrogens from the age of 12 yr. Adult height gain (adult height minus predicted adult height) and safety parameters were systematically assessed. Results: Compared with GH&#43;Pl, GH&#43;Ox 0.03 increased adult height gain in the intention-to-treat analysis (mean &#43;/- sd, 9.5 &#43;/- 4.7 vs. 7.2 &#43;/- 4.0 cm, P = 0.02) and per-protocol analysis (9.8 &#43;/- 4.9 vs. 6.8 &#43;/- 4.4 cm, P = 0.02). Partly due to accelerated bone maturation (P &lt; 0.001), adult height gain on GH&#43;Ox 0.06 was not significantly different from that on GH&#43;Pl (8.3 &#43;/- 4.7 vs. 7.2 &#43;/- 4.0 cm, P = 0.3). Breast development was slower on GH&#43;Ox (GH&#43;Ox 0.03, P = 0.02; GH&#43;Ox 0.06, P = 0.05), and more girls reported virilization on GH&#43;Ox 0.06 than on GH&#43;Pl (P &lt; 0.001). Conclusions: In GH-treated girls with TS, we discourage the use of the conventional Ox dosage (0.06 mg/kg. d) because of its low benefit to risk ratio. The addition of Ox 0.03 mg/kg. d modestly increases adult height gain and has a fairly good safety profile, except for some deceleration of breast development. JID: 0375362; 0 (Androgens); 0 (Recombinant Proteins); 12629-01-5 (Human Growth Hormone); 53-39-4 (Oxandrolone); 2010/01/08 [aheadofprint]; ppublish">

  
  <link rel="alternate" hreflang="en-us" href="/publication/2010-01-01_menke2010/">

  


  

  

  

  
  
  
  <meta name="theme-color" content="#4caf50">
  

  
  
  
  
    
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/twitter-bootstrap/4.1.3/css/bootstrap.min.css" integrity="sha256-eSi1q2PG6J7g7ib17yAaWMcrr5GrtohYChqibrV7PBE=" crossorigin="anonymous">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/academicons/1.8.6/css/academicons.min.css" integrity="sha256-uFVgMKfistnJAfoCUQigIl+JfUaP47GrRKjf6CTPVmw=" crossorigin="anonymous">
    <link rel="stylesheet" href="https://use.fontawesome.com/releases/v5.4.1/css/all.css" integrity="sha384-5sAR7xN1Nv6T6+dT2mhtzEpVJvfS3NScPQTrOxhwjIuvcA67KV2R5Jz6kr4abQsz" crossorigin="anonymous">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.2.5/jquery.fancybox.min.css" integrity="sha256-ygkqlh3CYSUri3LhQxzdcm0n1EQvH2Y+U5S2idbLtxs=" crossorigin="anonymous">

    
    
    
      
    
    
      
      
        <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.12.0/styles/github.min.css" crossorigin="anonymous">
      
    

    

    

  

  
  
  <link rel="stylesheet" href="//fonts.googleapis.com/css?family=Montserrat:400,700|Roboto:400,400italic,700|Roboto+Mono">
  

  <link rel="stylesheet" href="/styles.css">
  

  
  
  

  
  <link rel="alternate" href="/index.xml" type="application/rss+xml" title="Stef van Buuren">
  <link rel="feed" href="/index.xml" type="application/rss+xml" title="Stef van Buuren">
  

  <link rel="manifest" href="/site.webmanifest">
  <link rel="icon" type="image/png" href="/img/icon.png">
  <link rel="apple-touch-icon" type="image/png" href="/img/icon-192.png">

  <link rel="canonical" href="/publication/2010-01-01_menke2010/">

  <meta property="twitter:card" content="summary_large_image">
  
  <meta property="og:site_name" content="Stef van Buuren">
  <meta property="og:url" content="/publication/2010-01-01_menke2010/">
  <meta property="og:title" content="Efficacy and safety of oxandrolone in growth hormone-treated girls with turner syndrome | Stef van Buuren">
  <meta property="og:description" content="Context and Objective: GH therapy increases growth and adult height in Turner syndrome (TS). The benefit to risk ratio of adding the weak androgen oxandrolone (Ox) to GH is unclear. Design and Participants: A randomized, placebo-controlled, double-blind, dose-response study was performed in 10 centers in The Netherlands. One hundred thirty-three patients with TS were included in age group 1 (2-7.99 yr), 2 (8-11.99 yr), or 3 (12-15.99 yr). Patients were treated with GH (1.33 mg/m(2). d) from baseline, combined with placebo (Pl) or Ox in low (0.03 mg/kg. d) or conventional (0.06 mg/kg. d) dose from the age of 8 yr and estrogens from the age of 12 yr. Adult height gain (adult height minus predicted adult height) and safety parameters were systematically assessed. Results: Compared with GH&#43;Pl, GH&#43;Ox 0.03 increased adult height gain in the intention-to-treat analysis (mean &#43;/- sd, 9.5 &#43;/- 4.7 vs. 7.2 &#43;/- 4.0 cm, P = 0.02) and per-protocol analysis (9.8 &#43;/- 4.9 vs. 6.8 &#43;/- 4.4 cm, P = 0.02). Partly due to accelerated bone maturation (P &lt; 0.001), adult height gain on GH&#43;Ox 0.06 was not significantly different from that on GH&#43;Pl (8.3 &#43;/- 4.7 vs. 7.2 &#43;/- 4.0 cm, P = 0.3). Breast development was slower on GH&#43;Ox (GH&#43;Ox 0.03, P = 0.02; GH&#43;Ox 0.06, P = 0.05), and more girls reported virilization on GH&#43;Ox 0.06 than on GH&#43;Pl (P &lt; 0.001). Conclusions: In GH-treated girls with TS, we discourage the use of the conventional Ox dosage (0.06 mg/kg. d) because of its low benefit to risk ratio. The addition of Ox 0.03 mg/kg. d modestly increases adult height gain and has a fairly good safety profile, except for some deceleration of breast development. JID: 0375362; 0 (Androgens); 0 (Recombinant Proteins); 12629-01-5 (Human Growth Hormone); 53-39-4 (Oxandrolone); 2010/01/08 [aheadofprint]; ppublish">
  
  
    
  <meta property="og:image" content="/img/icon-192.png">
  <meta property="og:locale" content="en-us">
  
  <meta property="article:published_time" content="2010-01-01T00:00:00&#43;00:00">
  
  <meta property="article:modified_time" content="2010-01-01T00:00:00&#43;00:00">
  

  

  

  <title>Efficacy and safety of oxandrolone in growth hormone-treated girls with turner syndrome | Stef van Buuren</title>

</head>
<body id="top" data-spy="scroll" data-target="#TableOfContents" data-offset="71" >
  <aside class="search-results" id="search">
  <div class="container">
    <section class="search-header fixed-top">

      <div class="row no-gutters justify-content-between mb-3">
        <div class="col-6">
          <h1>Search</h1>
        </div>
        <div class="col-6 col-search-close">
          <a class="js-search" href="#"><i class="fas fa-times-circle text-muted" aria-hidden="true"></i></a>
        </div>
      </div>

      <div id="search-box">
        
        <input name="q" id="search-query" placeholder="Search..." autocapitalize="off"
        autocomplete="off" autocorrect="off" role="textbox" spellcheck="false" type="search">
        
      </div>

    </section>
    <section class="section-search-results">

      <div id="search-hits">
        
      </div>

    </section>
  </div>
</aside>


<nav class="navbar navbar-light fixed-top navbar-expand-lg py-0" id="navbar-main">
  <div class="container">

    
      <a class="navbar-brand" href="/">Stef van Buuren</a>
      
      <button type="button" class="navbar-toggler" data-toggle="collapse"
              data-target="#navbar" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
        <span><i class="fas fa-bars"></i></span>
      </button>
      

    
    <div class="collapse navbar-collapse" id="navbar">

      
      
      <ul class="navbar-nav ml-auto">
        

        

        
        
        
          
        

        <li class="nav-item">
          <a class="nav-link" href="/#about">
            
            <span>Home</span>
            
          </a>
        </li>

        
        

        

        
        
        
          
        

        <li class="nav-item">
          <a class="nav-link" href="/#publications_selected">
            
            <span>Publications</span>
            
          </a>
        </li>

        
        

        

        
        
        
          
        

        <li class="nav-item">
          <a class="nav-link" href="/#posts">
            
            <span>Posts</span>
            
          </a>
        </li>

        
        

        

        
        
        
          
        

        <li class="nav-item">
          <a class="nav-link" href="/#projects">
            
            <span>Projects</span>
            
          </a>
        </li>

        
        

        

        
        
        
          
        

        <li class="nav-item">
          <a class="nav-link" href="/#teaching">
            
            <span>Teaching</span>
            
          </a>
        </li>

        
        

        

        
        
        
          
        

        <li class="nav-item">
          <a class="nav-link" href="/#contact">
            
            <span>Contact</span>
            
          </a>
        </li>

        
        

      

        

        
        <li class="nav-item">
          <a class="nav-link js-search" href="#"><i class="fas fa-search" aria-hidden="true"></i></a>
        </li>
        

        
      </ul>

    </div>
  </div>
</nav>

<div class="pub" itemscope itemtype="http://schema.org/CreativeWork">

  












  

  
  
  
<div class="article-container pt-3">
  <h1 itemprop="name">Efficacy and safety of oxandrolone in growth hormone-treated girls with turner syndrome</h1>

  

  
    

<div class="article-metadata">

  
  
  
  <div>
    <span itemscope itemprop="author" itemtype="http://schema.org/Person">
      <span itemprop="name">L.A. Menke</span>
    </span>, 
    <span itemscope itemprop="author" itemtype="http://schema.org/Person">
      <span itemprop="name">T.C. Sas</span>
    </span>, 
    <span itemscope itemprop="author" itemtype="http://schema.org/Person">
      <span itemprop="name">S.M.P.F. de Muinck Keizer-Schrama</span>
    </span>, 
    <span itemscope itemprop="author" itemtype="http://schema.org/Person">
      <span itemprop="name">G.R. Zandwijken</span>
    </span>, 
    <span itemscope itemprop="author" itemtype="http://schema.org/Person">
      <span itemprop="name">M.A. de Ridder</span>
    </span>, 
    <span itemscope itemprop="author" itemtype="http://schema.org/Person">
      <span itemprop="name">R.J. Odink</span>
    </span>, 
    <span itemscope itemprop="author" itemtype="http://schema.org/Person">
      <span itemprop="name">M. Jansen</span>
    </span>, 
    <span itemscope itemprop="author" itemtype="http://schema.org/Person">
      <span itemprop="name">H.A. Delemarre-van de Waal</span>
    </span>, 
    <span itemscope itemprop="author" itemtype="http://schema.org/Person">
      <span itemprop="name">W.H. Stokvis-Brantsma</span>
    </span>, 
    <span itemscope itemprop="author" itemtype="http://schema.org/Person">
      <span itemprop="name">J.J. Waelkens</span>
    </span>, 
    <span itemscope itemprop="author" itemtype="http://schema.org/Person">
      <span itemprop="name">C. Westerlaken</span>
    </span>, 
    <span itemscope itemprop="author" itemtype="http://schema.org/Person">
      <span itemprop="name">H.M. Reeser</span>
    </span>, 
    <span itemscope itemprop="author" itemtype="http://schema.org/Person">
      <span itemprop="name">A.S. van Trotsenburg</span>
    </span>, 
    <span itemscope itemprop="author" itemtype="http://schema.org/Person">
      <span itemprop="name">E.F. Gevers</span>
    </span>, 
    <span itemscope itemprop="author" itemtype="http://schema.org/Person">
      <span itemprop="name"><strong>S. van Buuren</strong></span>
    </span>, 
    <span itemscope itemprop="author" itemtype="http://schema.org/Person">
      <span itemprop="name">P.H. Dejonckere</span>
    </span>, 
    <span itemscope itemprop="author" itemtype="http://schema.org/Person">
      <span itemprop="name">A.C. Hokken-Koelega</span>
    </span>, 
    <span itemscope itemprop="author" itemtype="http://schema.org/Person">
      <span itemprop="name">B.J. Otten</span>
    </span>, 
    <span itemscope itemprop="author" itemtype="http://schema.org/Person">
      <span itemprop="name">J.M. Wit</span>
    </span>
    
  </div>
  

  <span class="article-date">
    
    <meta content="2010-01-01 00:00:00 &#43;0000 UTC" itemprop="datePublished">
    <time datetime="2010-01-01 00:00:00 &#43;0000 UTC" itemprop="dateModified">
      2010-01-01
    </time>
  </span>
  <span itemscope itemprop="publisher" itemtype="http://schema.org/Person">
    <meta itemprop="name" content="Stef van Buuren">
  </span>

  

  
  

  

  
  
<div class="share-box" aria-hidden="true">
  <ul class="share">
    <li>
      <a class="twitter"
         href="https://twitter.com/intent/tweet?text=Efficacy%20and%20safety%20of%20oxandrolone%20in%20growth%20hormone-treated%20girls%20with%20turner%20syndrome&amp;url=%2fpublication%2f2010-01-01_menke2010%2f"
         target="_blank" rel="noopener">
        <i class="fab fa-twitter"></i>
      </a>
    </li>
    <li>
      <a class="facebook"
         href="https://www.facebook.com/sharer.php?u=%2fpublication%2f2010-01-01_menke2010%2f"
         target="_blank" rel="noopener">
        <i class="fab fa-facebook-f"></i>
      </a>
    </li>
    <li>
      <a class="linkedin"
         href="https://www.linkedin.com/shareArticle?mini=true&amp;url=%2fpublication%2f2010-01-01_menke2010%2f&amp;title=Efficacy%20and%20safety%20of%20oxandrolone%20in%20growth%20hormone-treated%20girls%20with%20turner%20syndrome"
         target="_blank" rel="noopener">
        <i class="fab fa-linkedin-in"></i>
      </a>
    </li>
    <li>
      <a class="weibo"
         href="http://service.weibo.com/share/share.php?url=%2fpublication%2f2010-01-01_menke2010%2f&amp;title=Efficacy%20and%20safety%20of%20oxandrolone%20in%20growth%20hormone-treated%20girls%20with%20turner%20syndrome"
         target="_blank" rel="noopener">
        <i class="fab fa-weibo"></i>
      </a>
    </li>
    <li>
      <a class="email"
         href="mailto:?subject=Efficacy%20and%20safety%20of%20oxandrolone%20in%20growth%20hormone-treated%20girls%20with%20turner%20syndrome&amp;body=%2fpublication%2f2010-01-01_menke2010%2f">
        <i class="fas fa-envelope"></i>
      </a>
    </li>
  </ul>
</div>


  

</div>

    














<div class="btn-links mb-3">
  
  








  
    
  


<a class="btn btn-outline-primary my-1 mr-1" href="/publications/2010%20Efficacy%20Oxandrolone%20-%20JECM.pdf" target="_blank" rel="noopener">
  PDF
</a>

















</div>


  
</div>



  <div class="article-container">

    
    <h3>Abstract</h3>
    <p class="pub-abstract" itemprop="text">Context and Objective: GH therapy increases growth and adult height in Turner syndrome (TS). The benefit to risk ratio of adding the weak androgen oxandrolone (Ox) to GH is unclear. Design and Participants: A randomized, placebo-controlled, double-blind, dose-response study was performed in 10 centers in The Netherlands. One hundred thirty-three patients with TS were included in age group 1 (2-7.99 yr), 2 (8-11.99 yr), or 3 (12-15.99 yr). Patients were treated with GH (1.33 mg/m(2). d) from baseline, combined with placebo (Pl) or Ox in low (0.03 mg/kg. d) or conventional (0.06 mg/kg. d) dose from the age of 8 yr and estrogens from the age of 12 yr. Adult height gain (adult height minus predicted adult height) and safety parameters were systematically assessed. Results: Compared with GH+Pl, GH+Ox 0.03 increased adult height gain in the intention-to-treat analysis (mean +/- sd, 9.5 +/- 4.7 vs. 7.2 +/- 4.0 cm, P = 0.02) and per-protocol analysis (9.8 +/- 4.9 vs. 6.8 +/- 4.4 cm, P = 0.02). Partly due to accelerated bone maturation (P &lt; 0.001), adult height gain on GH+Ox 0.06 was not significantly different from that on GH+Pl (8.3 +/- 4.7 vs. 7.2 +/- 4.0 cm, P = 0.3). Breast development was slower on GH+Ox (GH+Ox 0.03, P = 0.02; GH+Ox 0.06, P = 0.05), and more girls reported virilization on GH+Ox 0.06 than on GH+Pl (P &lt; 0.001). Conclusions: In GH-treated girls with TS, we discourage the use of the conventional Ox dosage (0.06 mg/kg. d) because of its low benefit to risk ratio. The addition of Ox 0.03 mg/kg. d modestly increases adult height gain and has a fairly good safety profile, except for some deceleration of breast development. JID: 0375362; 0 (Androgens); 0 (Recombinant Proteins); 12629-01-5 (Human Growth Hormone); 53-39-4 (Oxandrolone); 2010/01/08 [aheadofprint]; ppublish</p>
    

    
    <div class="row">
      <div class="col-md-1"></div>
      <div class="col-md-10">
        <div class="row">
          <div class="col-12 col-md-3 pub-row-heading">Type</div>
          <div class="col-12 col-md-9">
            
            <a href="/publication/#2">
              Journal article
            </a>
            
          </div>
        </div>
      </div>
      <div class="col-md-1"></div>
    </div>
    <div class="d-md-none space-below"></div>
    

    
    <div class="row">
      <div class="col-md-1"></div>
      <div class="col-md-10">
        <div class="row">
          <div class="col-12 col-md-3 pub-row-heading">Publication</div>
          <div class="col-12 col-md-9">J. Clin. Endocrinol. Metab., (95), 3, <em>1151&ndash;1160</em></div>
        </div>
      </div>
      <div class="col-md-1"></div>
    </div>
    <div class="d-md-none space-below"></div>
    

    <div class="row">
      <div class="col-md-1"></div>
      <div class="col-md-10">
        <div class="row">
          <div class="col-12 col-md-3 pub-row-heading">Date</div>
          <div class="col-12 col-md-9" itemprop="datePublished">
            January, 2010
          </div>
        </div>
      </div>
      <div class="col-md-1"></div>
    </div>
    <div class="d-sm-none space-below"></div>

    <div class="space-below"></div>

    <div class="article-style"></div>

    




    



  







  </div>
</div>



<div class="container">
  <footer class="site-footer">
  
  <p class="powered-by">
    <a href="/privacy/">Privacy Policy</a>
  </p>
  

  <p class="powered-by">
    &copy; 2018 &middot; 

    Powered by the
    <a href="https://sourcethemes.com/academic/" target="_blank" rel="noopener">Academic theme</a> for
    <a href="https://gohugo.io" target="_blank" rel="noopener">Hugo</a>.

    
    <span class="float-right" aria-hidden="true">
      <a href="#" id="back_to_top">
        <span class="button_icon">
          <i class="fas fa-chevron-up fa-2x"></i>
        </span>
      </a>
    </span>
    
  </p>
</footer>

</div>


<div id="modal" class="modal fade" role="dialog">
  <div class="modal-dialog">
    <div class="modal-content">
      <div class="modal-header">
        <h5 class="modal-title">Cite</h5>
        <button type="button" class="close" data-dismiss="modal" aria-label="Close">
          <span aria-hidden="true">&times;</span>
        </button>
      </div>
      <div class="modal-body">
        <pre><code class="tex hljs"></code></pre>
      </div>
      <div class="modal-footer">
        <a class="btn btn-outline-primary my-1 js-copy-cite" href="#" target="_blank">
          <i class="fas fa-copy"></i> Copy
        </a>
        <a class="btn btn-outline-primary my-1 js-download-cite" href="#" target="_blank">
          <i class="fas fa-download"></i> Download
        </a>
        <div id="modal-error"></div>
      </div>
    </div>
  </div>
</div>

    

    
    
    
    <script src="/js/mathjax-config.js"></script>
    

    
    
    
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery/3.3.1/jquery.min.js" integrity="sha512-+NqPlbbtM1QqiK8ZAo4Yrj2c4lNQoGv8P79DPtKzj++l5jnN39rHA/xsqn8zE9l0uSoxaCdrOgFs6yjyfbBxSg==" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.imagesloaded/4.1.3/imagesloaded.pkgd.min.js" integrity="sha512-umsR78NN0D23AzgoZ11K7raBD+R6hqKojyBZs1w8WvYlsI+QuKRGBx3LFCwhatzBunCjDuJpDHwxD13sLMbpRA==" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/twitter-bootstrap/4.1.3/js/bootstrap.min.js" integrity="sha256-VsEqElsCHSGmnmHXGQzvoWjWwoznFSZc6hs7ARLRacQ=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.isotope/3.0.4/isotope.pkgd.min.js" integrity="sha512-VDBOIlDbuC4VWxGJNmuFRQ0Li0SKkDpmGyuhAG5LTDLd/dJ/S0WMVxriR2Y+CyPL5gzjpN4f/6iqWVBJlht0tQ==" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.2.5/jquery.fancybox.min.js" integrity="sha256-X5PoE3KU5l+JcX+w09p/wHl9AzK333C4hJ2I9S5mD4M=" crossorigin="anonymous"></script>

      
        
        <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.12.0/highlight.min.js" integrity="sha256-/BfiIkHlHoVihZdc6TFuj7MmJ0TWcWsMXkeDFwhi0zw=" crossorigin="anonymous"></script>
        
        <script src="//cdnjs.cloudflare.com/ajax/libs/highlight.js/9.12.0/languages/R.min.js"></script>
        
      

      
      
      <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.4/MathJax.js?config=TeX-AMS_CHTML-full" integrity="sha256-GhM+5JHb6QUzOQPXSJLEWP7R73CbkisjzK5Eyij4U9w=" crossorigin="anonymous" async></script>
      
    

    
    

    
    
    

    
    
    <script>hljs.initHighlightingOnLoad();</script>
    

    
    
    <script>
      const search_index_filename = "/index.json";
      const i18n = {
        'placeholder': "Search...",
        'results': "results found",
        'no_results': "No results found"
      };
      const content_type = {
        'post': "Posts",
        'project': "Projects",
        'publication' : "Publications",
        'talk' : "Talks"
        };
    </script>
    

    
    

    
    
    <script id="search-hit-fuse-template" type="text/x-template">
      <div class="search-hit" id="summary-{{key}}">
      <div class="search-hit-content">
        <div class="search-hit-name">
          <a href="{{relpermalink}}">{{title}}</a>
          <div class="article-metadata search-hit-type">{{type}}</div>
          <p class="search-hit-description">{{snippet}}</p>
        </div>
      </div>
      </div>
    </script>
    

    
    
    <script src="https://cdnjs.cloudflare.com/ajax/libs/fuse.js/3.2.1/fuse.min.js" integrity="sha256-VzgmKYmhsGNNN4Ph1kMW+BjoYJM2jV5i4IlFoeZA9XI=" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/mark.js/8.11.1/jquery.mark.min.js" integrity="sha256-4HLtjeVgH0eIB3aZ9mLYF6E8oU5chNdjU6p6rrXpl9U=" crossorigin="anonymous"></script>
    

    
    

    
    
    
    
    
    
    
    
    <script src="/js/academic.min.74b0d3361475b08c40cf31120e82937b.js"></script>

    

  </body>
</html>

